Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paclitaxel + taselisib
- Development stage
- Unknown
- Lead developer
- Genentech
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination of paclitaxel, a taxane chemotherapy agent, and taselisib, a selective potent inhibitor of class I PI3K p110α, p110γ, and p110δ isoforms. Taselisib has preferential activity on mutant forms of p110α and targets its ATP-binding pocket, leading to inhibition of downstream signaling events that regulate tumor cell proliferation. This combination was investigated in clinical trials for the treatment of advanced breast cancer and non-small cell lung cancer.
- Other names
- GDC-0032 + paclitaxeltaselisib + paclitaxel
02
Targets
TUBB (Tubulin (alpha and beta subunits))PIK3CA (Phosphoinositide 3-kinase alpha)
Beyond the preview
Go deeper on paclitaxel + taselisib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paclitaxel + taselisib.